• Trump signs order to expeditiously review psychedelics, emphasizing veterans' benefits.
• The directive focuses on ibogaine, a psychedelic drug used to treat PTSD and mental health issues.
• The FDA will issue national priority vouchers for expedient drug approvals.
• A significant federal investment of $50 million is allocated for ibogaine research.
• Veteran organizations support the move, citing potential mental health benefits.

On Saturday, US President Donald Trump signed an executive order aimed at expediting the review of psychedelic drugs, particularly ibogaine, which has garnered attention for its potential to assist combat veterans suffering from conditions like post-traumatic stress disorder (PTSD). "Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump stated during the signing ceremony held in the Oval Office, as reported by SCMP, Channel News Asia, India Times, and LA Times.

The executive order instructs the US Food and Drug Administration (FDA) to accelerate the approval process for ibogaine and other psychedelics, an initiative supported by Health Secretary Robert F. Kennedy Jr. and various veteran advocacy groups. Kennedy touted ibogaine as a potential alternative treatment for mental health conditions, which has recently gained bipartisan support among lawmakers, according to SCMP, Channel News Asia, and LA Times.

Trump's administration is taking steps to facilitate faster clinical trials, particularly for ibogaine, which has historically faced scrutiny due to safety risks such as cardiovascular issues. The FDA will provide national priority vouchers intended to expedite drug reviews significantly, with decisions on these substances expected as early as summer, reports Channel News Asia and India Times.

The executive order includes a commitment of $50 million for federal research on ibogaine, a funding initiative that advocates believe may pave the way for further state and federal collaborations on psychedelic treatment programs. "We will continue working in Congress to build on the president's leadership and expand access to this life-saving treatment," said Rep. Morgan Luttrell, a Texas Republican, suggesting ongoing legislative efforts to promote such therapies, according to LA Times and Channel News Asia.

While ibogaine remains classified as a Schedule I substance under federal law, Trump's directive forms part of a broader move to re-examine the regulatory landscape surrounding psychedelic drugs. Advocates argue that the executive order might provide the necessary cover for state-level initiatives aimed at funding research on psychedelics, as indicated by Ismail Lourido Ali from the Multidisciplinary Association for Psychedelic Studies, according to SCMP and LA Times.